Login to Your Account



We Chelsea about That . . .

Phase III Endpoint Switcheroo: Proceed at Your (Lesser?) Risk

By Randy Osborne


Monday, November 9, 2009
Chelsea Therapeutics Inc.'s earnings-call news last week that the firm is asking the FDA to allow an endpoint change in the still-blinded, second Phase III test with droxidopa for low blood pressure caused some Wall Street ripples, and sparked speculation on the wisdom of such a move.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription